NasdaqGS - Nasdaq Real Time Price ? USD Halozyme Therapeutics, Inc. (HALO) Follow Compare 53.82 -0.13 (-0.24%) At close: October 15 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options Investors need to pay close attention to Halozyme Therapeutics (HALO) stock based on the movements in the options market lately. Zacks ? yesterday HALO -0.24% Why Investors Need to Take Advantage of These 2 Medical Stocks Now Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. Zacks ? 7 days ago HALO -0.24% TMDX Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. Zacks ? 8 days ago HALO -0.24% Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE? Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme's ENHANZE? drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery. argenx, a global immunology company, now has exclusively licensed ENHANZE? for a total of six targets, including for the neonatal Fc receptor (FcRn) tar PR Newswire ? 13 days ago HALO -0.24% High Growth Tech Stocks In The United States To Watch Over the last 7 days, the market has remained flat, but it is up 34% over the past year with earnings expected to grow by 15% per annum over the next few years. In this context, identifying high growth tech stocks that can capitalize on these favorable conditions is crucial for investors seeking robust returns. Simply Wall St. ? 13 days ago GDRX HALO -0.24% VTEX Are You a Value Investor? This 1 Stock Could Be the Perfect Pick Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Zacks ? 14 days ago HALO -0.24% FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech The authorisation enables a twice-yearly, ten-minute subcutaneous injection to treat RMS and PPMS. Pharmaceutical Technology ? 30 days ago ROG.SW HALO -0.24% Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO? with ENHANZE? for People with Relapsing and Primary Progressive Multiple Sclerosis Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO? (ocrelizumab and hyaluronidase-ocsq) with Halozyme's ENHANZE? drug delivery technology for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) as a twice-a-year, approximately 10-minute subcutaneous (SC) injection to be administered by a healthcare practitioner. PR Newswire ? last month HALO -0.24% Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza? With ENHANZE? for Multiple Types of Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq Hybreza? (atezolizumab and hyaluronidase-tqjs) with Halozyme's ENHANZE? drug delivery technology. Tecentriq Hybreza? can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) infusion of Tecentriq? (atezolizumab). The treatment will be available in the U.S. for all approved adult indicati PR Newswire ? last month HALO -0.24% Why This 1 Value Stock Could Be a Great Addition to Your Portfolio Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Zacks ? last month HALO -0.24% Q1 2025 Avid Bioservices Inc Earnings Call Q1 2025 Avid Bioservices Inc Earnings Call Thomson Reuters StreetEvents ? last month CDMO HALO -0.24% Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report? Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? last month SRPT HALO -0.24% Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue? Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? last month HALO -0.24% Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Zacks ? last month HALO -0.24% Halozyme to Present at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to present and host investor meetings at the following investor conferences. PR Newswire ? last month HALO -0.24% Exploring Three High Growth Tech Stocks in the United States Over the last 7 days, the market has remained flat, but it is up 23% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors seeking robust returns. Simply Wall St. ? last month NTRA HALO -0.24% VCEL Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Zacks ? last month HALO -0.24% Halozyme Earnings, Guidance Point to Bullish Future Strong revenue growth and a bright outlook have Halozyme Therapeutics, Inc. (HALO) shares rising. FX Empire ? last month HALO -0.24% Questor: This biotech firm is profiting from an overlooked area of healthcare It’s one thing to develop a life-changing drug but another entirely to work out the best way to get it into patients. The Telegraph ? last month HALO -0.24% Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO) On August 14, 2024, Matthew Posard, Director at Halozyme Therapeutics Inc (NASDAQ:HALO), executed a sale of 29,881 shares of the company. The transaction was filed on the same day through an SEC Filing. Following this transaction, the insider now owns 69,874 shares of Halozyme Therapeutics Inc. GuruFocus.com ? 2 months ago HALO -0.24% Performance Overview Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return HALO S&P 500 YTD +45.62% +21.92% 1-Year +47.25% +34.37% 3-Year +40.08% +31.03%
